Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Blood

Volumn 123, Issue 9, 2014, Pages 1309-1318

  Kantarjian, Hagop M ^a   Cortes, Jorge E ^a   Kim, Dong Wook ^b   Khoury, H Jean ^c   Brümmendorf, Tim H ^d,e   Porkka, Kimmo ^f   Martinelli, Giovanni ^g   Durrant, Simon ^h   Leip, Eric ⁱ   Kelly, Virginia ⁱ   Turnbull, Kathleen ⁱ   Besson, Nadine ⁱ   Gambacorti Passerini, Carlo ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b The Catholic University of Korea   (South Korea)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOSUTINIB; DASATINIB; IMATINIB; INTERFERON; LOPERAMIDE; NILOTINIB; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKEMIA; LEUKOPENIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OPEN STUDY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; RHINOPHARYNGITIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84896622957     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-513937     Document Type: Article

References (21)

1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 1. 2014. Available at: http://www.nccn.org/professionals/ physician-gls/pdf/cml.pdf. Accessed October 3, 2013.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Acute Lymphoblastic Leukemia. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/all.pdf. Accessed October 3, 2013.
4. O'Brien SG, Guilhot F, Larson RA, et al; for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. (Pubitemid 36302244)
5. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
6. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-1647. (Pubitemid 46594119)
7. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356. (Pubitemid 46652483)
8. Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist. 2008;13(4):424-434. (Pubitemid 351679922)
9. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123-1129.
10. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.
11. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66(23):11314-11322. (Pubitemid 46009962)
12. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009;23(3):477-485.
13. BOSULIF® (bosutinib). Full prescribing information. New York, NY: Pfizer Labs; 2012.
14. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576.
15. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/ or nilotinib therapy failure. Blood. 2012;119(15):3403-3412.
16. TASIGNA® (nilotinib). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
17. SPRYCEL® (dasatinib). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
18. GLEEVEC® (imatinib mesylate). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
19. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486-3492.
20. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232-240.
21. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141-1145.